title: Serum acute phase protein concentrations after hysterectomy with and without low-molecular-weight heparin thrombosis prophylaxis.
abstract: Background. Low-molecular-weight heparin (LMWH) is recommended for venous thrombosis prophylaxis. There are several lines of evidence that heparins exhibit anti-inflammatory properties in addition to their anticoagulant activity. Therefore, we decided to estimate the concentrations of C-reactive protein (CRP) and haptoglobin, as acute-phase proteins, in the blood serum of patients who underwent total abdominal hysterectomy with and without the LMWH administration. Method. Forty-two women were studied, including 26 patients treated with enoxaparin and a group of 16 women without thrombosis prophylaxis. Haptoglobin and CRP concentrations were measured in serum samples obtained before the operation and also 8, 24, 48, 72, 96, and 192 hr after surgery. Results. Serum CRP level measured 8 hr after the operation was significantly higher in the group without thrombosis prophylaxis, however, no statistically significant differences in the concentration of CRP between studied groups in the other time periods were found. There were no statistically significant differences in serum haptoglobin levels between the groups of patients in all time periods. Conclusion. Administration of low-molecular-weight heparin may affect CRP production, however, further studies are still needed in order to clarify the exact immunosuppressive action of heparins.
authors: First Department of Gynecology, University School of Medicine, ul. Staszica 16, 20-081 Lublin, Poland.
authors: Monika
authors: M
authors: Maciejczyk-Pencuła
authors: Grzegorz
authors: G
authors: Polak
authors: Jan
authors: J
authors: Kotarski
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis / Q000187:drug effects; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis* / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017984:Enoxaparin / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006242:Haptoglobins / Q000032:analysis* / Q000187:drug effects; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects / Q000379:methods*; D007279:Injections, Subcutaneous; D008875:Middle Aged; D019990:Perioperative Care; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D012016:Reference Values; D018570:Risk Assessment; D016896:Treatment Outcome; D014591:Uterine Diseases / Q000473:pathology / Q000601:surgery; D020246:Venous Thrombosis / Q000517:prevention & control*
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; D017984:Enoxaparin; D006242:Haptoglobins; D002097:C-Reactive Protein